Allografting for chronic myeloid leukaemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for chronic myeloid leukemia (CML).
• Human leukocyte antigen (HLA) matched related donors provide the highest probability of treatment-free survival for CML patients in chronic phase.
• Limited availability of HLA-matched related donors restricts HSCT to a small percentage of eligible patients.

Purpose of the Study:

• To review the factors influencing outcomes in HSCT for CML.
• To discuss alternative donor sources for CML patients.
• To highlight strategies for improving HSCT success rates in CML.

Main Methods:

• Review of existing literature on HSCT for CML.
• Analysis of factors affecting HSCT outcomes, including donor type, disease status, and patient characteristics.
• Discussion of the role of unrelated donor registries.

Main Results:

• Factors such as delayed transplantation, patient-donor gender mismatch, patient age, and prior busulfan treatment negatively impact HSCT outcomes.
• HLA-matched related donor transplants are feasible for less than 15% of newly diagnosed CML patients.
• The expansion of unrelated donor registries has increased the availability of HLA-compatible unrelated donors.

Conclusions:

• Early HSCT, optimal donor matching, and advancements in preventing graft-versus-host disease and infections are crucial for improving survival in CML patients.
• Alternative donor sources, including unrelated donors, expand HSCT accessibility.
• Continued research into novel therapeutic strategies is essential for enhancing HSCT efficacy in CML management.